CD274 and glioblastoma: Despite being an effective immunomodulatory method, PD-1/PD-L1 checkpoint pathway blockade faces some challenges, such as the different responses of various genomic subtypes to the blockade, inability to distinguish between primary and recurrent glioblastoma therapy, and which agents should be used in combination if used in combination.